SGLT2 inhibitors vs. GLP-1 receptor agonists and clinical outcomes in patients with diabetes with/without atrial fibrillation.
Yi-Hsin ChanAbigail Louise D TeShao-Wei ChenHsin-Fu LeePei-Ru LiYung-Hsin YehChi-Tai KuoLai-Chu SeeGregory Y H LipPublished in: The Journal of clinical endocrinology and metabolism (2024)
Considering the high risk of developing HF and/or high prevalence of concomitant HF in patients with diabetes, whether SGLT2i should be the preferred treatment to GLP-1RA for such a high-risk population requires further investigation.
Keyphrases
- atrial fibrillation
- rheumatoid arthritis
- acute heart failure
- heart failure
- catheter ablation
- left atrial
- left atrial appendage
- oral anticoagulants
- disease activity
- direct oral anticoagulants
- combination therapy
- ankylosing spondylitis
- acute coronary syndrome
- systemic sclerosis
- left ventricular
- idiopathic pulmonary fibrosis